Abstract: According to some embodiments, re-programmable and/or reconfigurable analog circuitry may be provided. An image interpreter (e.g., a Micro Control Unit (“MCU”)) may be configured to receive and store an image, generated for a particular application, to facilitate variation trimming of the re-programmable and/or reconfigurable analog circuitry. The variation trimming may, for example, be performed during production of the re-programmable and/or reconfigurable analog circuitry or post-production of circuitry, in the field, after the circuitry is provided to a customer.

Abstract: A distributed collaboration interface interacts with a workflow system. A job of the workflow system comprises a series of tasks. Each task of a single job may be performed via the collaboration interface by multiple principals. When a first principal is performing a first task of the job through a first instance of the distributed collaboration interface, second principals performing second tasks of the job may view but may not modify the first task. Moreover, second instances of the distributed collaboration interface associated with the second principals update in real time to lock the first task from being modified by the second principals as soon as the first principal obtains control of the first task within the first instance of the collaboration interface.

Abstract: According to some embodiments, re-programmable and/or reconfigurable analog circuitry may be provided. An image interpreter (e.g., a Micro Control Unit (“MCU”)) may be configured to receive and store an image, generated for a particular application, to facilitate variation trimming of the re-programmable and/or reconfigurable analog circuitry. The variation trimming may, for example, be performed during production of the re-programmable and/or reconfigurable analog circuitry or post-production of circuitry, in the field, after the circuitry is provided to a customer.

Abstract: The invention relates to a solid ?9-THC composition containing ?9-THC and a powder former and having a molar ratio of ?9-THC to powder former to form a flowable ?9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, ?-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid ?9-THC composition of the invention. The ?9-THC may be synthetic ?9-THC or may be extracted ?9-THC.

Abstract: Provided herein are methods of manipulating ARID5B expression in immune cells such NK cells, T cells, and T cell and NK cell progenitors to enhance their persistence and function in vivo. Also provided herein are modified immune cells and compositions comprising such modified cells for anti-cancer, anti-viral, and other immunotherapies. In some embodiments, immune cells are genetically modified to increase ARID5B expression and, thus, improve persistence, increase in vivo anti-tumor efficacy, and increase viability and functionality of the modified cells after freezing and thawing.

Abstract: The invention relates to a solid ?9-THC composition containing ?9-THC and a powder former and having a molar ratio of ?9-THC to powder former to form a flowable ?9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, ?-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid ?9-THC composition of the invention. The ?9-THC may be synthetic ?9-THC or may be extracted ?9-THC.

Abstract: A distributed collaboration interface interacts with a workflow system. A job of the workflow system comprises a series of tasks. Each task of a single job may be performed via the collaboration interface by multiple principals. When a first principal is performing a first task of the job through a first instance of the distributed collaboration interface, second principals performing second tasks of the job may view but may not modify the first task. Moreover, second instances of the distributed collaboration interface associated with the second principals update in real time to lock the first task from being modified by the second principals as soon as the first principal obtains control of the first task within the first instance of the collaboration interface.

Abstract: Ultrasound imaging uses matrix arrays. A common design is used for an integrated circuit. The integrated circuit is programmable so that the same design of integrated circuit may be used with different types of arrays, such as matrix arrays with different pitches. The design allows for one element to connect with multiple, identical processing circuits of the signal processor.

Abstract: The present application relates to biotechnological fluid treating, such as biopharmaceutical liquids in order to obtain products such as monoclonal antibodies, vaccines or recombinant proteins, and particularly to a system for treating a biotechnical fluid, having a bioprocess machine and at least one bioprocess machine helper, configured to connect to each other and each comprising a controller, in turn comprising a machine-to-machine communication tool configured for connecting to a network.

Abstract: An underwater light having light emitting units positioned around the central axis of a cylindrical structure. The light emitting units project light in multiple directions around the central axis of the cylindrical structure. A transparent cover is located over the light emittign units and a power cord is attached to the underwater light. The power cord adapted to be connected to a power source out of the water to provide power to the underwater light when the underwater light is in the water.

Abstract: The present application relates to biotechnological fluid treating, such as biopharmaceutical liquids in order to obtain products such as monoclonal antibodies, vaccines or recombinant proteins, and particularly to a system for treating a biotechnical fluid, having a bioprocess machine and at least one bioprocess machine helper, configured to connect to each other and each comprising a controller, in turn comprising a machine-to-machine communication tool configured for connecting to a network

Abstract: Embodiments disclosed herein include a computer system. In an embodiment, the computer system comprises a printed circuit board assembly (PCBA) with a first surface and a second surface opposite from the first surface. In an embodiment, a first computer processor module is coupled to the first surface of the PCBA, and a second computer processor module is coupled to the second surface of the PCBA. In an embodiment, the first computer processor module is communicatively coupled to the second computer processor module through an electrical path that passes through a thickness of the PCBA.

Abstract: An underwater dock light having an adjustable anchoring system having a capturing assembly with an upper capturing housing located opposite a lower capturing housing. The upper capturing housing can have at least one cord opening configured to receive a cord. The upper capturing housing can have a cord capturing structure. The cord is configured to contact a portion of the cord capturing structure. A fastener is configured to connect the upper capturing housing to the lower capturing housing. The cord is captured between the cord capturing structure of the upper capturing housing and a surface of the lower capturing housing. An anchoring weight is configured to connect to the capturing assembly. The anchoring weight has an opening. The upper capturing housing and lower capturing housing are configured to retain the anchoring weight.

Abstract: A beverage dispensing head includes a housing having a front, a rear, and a base that extends between the front and the rear. A mixing nozzle is configured to dispense a flow of beverage via the base. A valve is configured to control the flow of beverage via the mixing nozzle, and a switch is movable into and between a closed position in which the valve opens the flow of beverage via the mixing nozzle and an open position in which the valve closes the flow of beverage via the mixing nozzle. A lighting module disposed in the housing is configured to illuminate the front of the housing and the base of the housing when the switch is moved into the closed position.

Abstract: The invention relates to a solid ?9-THC composition containing ?9-THC and a powder former and having a molar ratio of ?9-THC to powder former to form a flowable ?9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, ?-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid ?9-THC composition of the invention. The ?9-THC may be synthetic ?9-THC or may be extracted ?9-THC.

Abstract: A collection system for monitoring conditions of a rack of animal cages. An animal caging system including a plurality of animal cages removably connected to an exhaust. A collection media cartridge is slidably received within an opening in a collection media housing dock. The collection media housing dock is positioned between an exhaust plenum of the rack an exhaust air inlet unit. Collection media is removably received in the collection media cartridge. Exhaust air dust clings to the collection media as exhaust from the animal cages flows along the length of the collection media. The collection media cartridge can be removed from the collection media housing dock and the collection media can be removed for sampling the exhaust.

Abstract: The invention relates to a solid ?9-THC composition containing ?9-THC and a powder former and having a molar ratio of ?9-THC to powder former to form a flowable ?9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, ?-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid ?9-THC composition of the invention. The ?9-THC may be synthetic ?9-THC or may be extracted ?9-THC.

Abstract: A custom foot orthotic and a system and a method for designing of a custom foot orthotic. The method includes: receiving 3D scan data of the patient's foot; receiving plantar pressure scan data of the patient's foot; establishing a desirable pressure distribution; generating an underfoot elevation profile relative to an elevation profile of the patient's foot in the 3D scan data; determining an internal density profile of the resulting foot orthotic 3D model by superimposing the desirable pressure distribution over the resulting foot orthotic 3D model and reducing or increasing density in regions of the foot orthotic 3D model based on the difference between an expected pattern of support and the desirable pressure distribution; and outputting the 3D model of the custom foot orthotic.

Abstract: The present disclosure relates to a method of treating female or male sexual dysfunction, wherein the method comprises orally administering to a female or male subject an effective amount of 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof.